Web-supported social network testing for HIV among men who have sex with men with a migration background : Protocol for a mixed methods pilot study

Acknowledgments The PREVENT project is funded by Aidsfonds (grants P-22603 and P-35609) as a high-risk high-gain project. We also thank the following people for their contributions: from Aidsfonds–Soa Aids Nederland, Suzan Bergh, Hanna Bos, Tatiana Mouhebati, and Marieke van den Borne; from the National Institute for Public Health and the Environment, Birgit van Benthem; from Amsterdam Public Health Service, Anders Boyd and Adriaan Tempert; from Utrecht University, John de Wit; from Maastricht University, Nicole Dukers; from Trial Data Solutions, Gerben Rienk Visser. The time2test website was developed by TjunaPeer reviewedPublisher PD

Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment - A Cross-sectional Study

Background: Steatotic liver disease is suggested to have a higher prevalence and severity in people with HIV (PHIV), including in those with a normal body mass index (BMI). In this study, we used data from the 2000HIV cohort to (1) assess the prevalence of liver steatosis and fibrosis in lean versus overweight/obese PHIV and (2) assess associations in these subgroups between steatosis and fibrosis with traditional risk factors and HIV-specific characteristics. Methods: The 2000HIV study cohort comprises 1895 virally suppressed PHIV that were included between 2019 and 2021 in 4 HIV treatment centers in the Netherlands. The majority (58.5%) underwent vibration-controlled transient elastography for the assessment of liver steatosis and fibrosis. The prevalence of steatosis (controlled attenuation parameter ≥263 dB/m) and fibrosis (liver stiffness measurement ≥7.0 kPa) was estimated. Multiple factors including HIV characteristics and antiretroviral drugs were tested in a logistic regression model for association with steatosis and fibrosis. Analyses were performed separately for lean (Asian descent: BMI &lt; 23 kg/m2, other descent: BMI &lt; 25 kg/m2) and overweight/obese (other BMI) participants. Results: Of 1050 PHIV including 505 lean and 545 overweight/obese PHIV, liver steatosis was observed in 37.7% of the overall study population, 19.7% of lean, and 54% of overweight/obese PHIV, whereas fibrosis was observed in 9.0% of the overall study population, 5.9% of lean, and 12.0% of overweight/obese PHIV. All associations with fibrosis and most associations with steatosis concerned metabolic factors such as type 2 diabetes mellitus (overall population: adjusted odds ratio [aOR] for steatosis: 2.3 [1.21-4.4], P =. 011; aOR for fibrosis: 3.7 [1.82-7.53], P &lt;. 001). Furthermore, in lean PLHIV, liver steatosis was associated with CD4 and CD8 counts at enrollment, dual therapy, and history of treatment with raltegravir (aOR: 3.6 [1.53-8.47], P =. 003), stavudine (aOR: 3.73 [1.69-8.2], P =. 001), and indinavir (aOR: 3.86 [1.59-9.37], P =. 003). These associations were not observed in overweight/obese PHIV. Conclusions: Liver steatosis was highly prevalent, affecting approximately one-fifth of lean PHIV and half of overweight/obese PHIV. Fibrosis was observed in a minority. Both steatosis and fibrosis were associated with traditional metabolic risk factors. In addition, (prior) exposure to specific antiretroviral drugs was associated liver steatosis in lean, but not in overweight/obese PHIV. Implementing increased screening protocols could enhance the identification of steatotic liver disease in lean PHIV.</p

DNA-ENCODED PEPTIDE LIBRARIES AND DRUG DISCOVERY

Over the past decade, several methods have been developed for the construction of DNA-encoded peptide libraries. The common principle behind all these methods is the establishment of a physical linkage between a displayed peptide and its encoding DNA. Vast libraries can be generated, binding peptides can be isolated with simple selections, and the sequences of selected peptides can be rapidly determined from the sequence of the linked DNA. As a result, DNAencoded libraries can provide specific ligands for essentially any protein. These ligands can be used to determine the natural binding specificities of protein–protein interactions, and this information can be used to identify natural binding partners or to aid the design of organic mimics. Binding peptides can also be used for target validation and the development of high-throughput screens for small-molecule libraries. Finally, binding peptides themselves could prove useful as drugs